14 Nov ‘Unprecedented’ pace of COVID-19 drug development pushing Madison companies to expand
In response to the uptick in production needs, Catalent accelerated its existing plans to open the new facilities.
Spurred on by the push to end the COVID-19 pandemic, Catalent Biologics is rapidly expanding its Madison facilities and staff to account for increased production of substances used by various pharmaceutical companies around the world.
Catalent manufactures the drug substances — or active ingredients — which are used to make the final drug given to patients. Now, the company is working to combat COVID-19 by working with pharmaceutical companies developing treatments and vaccines.
In response to the uptick in production needs, Catalent accelerated its existing plans to open the new facilities. The 60,000-square-foot manufacturing expansion to the facility is now on schedule to open halfway through next year.
Catalent is far from the only business in Madison fighting to end the pandemic.